In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development

@article{Steven2017InVM,
  title={In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development},
  author={J. Steven and M. R. M{\"u}ller and M. F. Carvalho and Obinna C. Ubah and M. Kovaleva and G. Donohoe and Thomas C. Baddeley and Dawn Cornock and K. Saunders and A. Porter and C. Barelle},
  journal={Frontiers in Immunology},
  year={2017},
  volume={8}
}
  • J. Steven, M. R. Müller, +8 authors C. Barelle
  • Published 2017
  • Biology, Medicine
  • Frontiers in Immunology
  • Molecular engineering to increase the percentage identity to common human immunoglobulin sequences of non-human therapeutic antibodies and scaffolds has become standard practice. This strategy is often used to reduce undesirable immunogenic responses, accelerating the clinical development of candidate domains. The first humanized shark variable domain (VNAR) was reported by Kovalenko and colleagues and used the anti-human serum albumin (HSA) domain, clone E06, as a model to construct a number… CONTINUE READING
    13 Citations

    Topics from this paper

    In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties.
    • 1
    Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability.
    • 6
    Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
    • 35
    • PDF

    References

    SHOWING 1-10 OF 46 REFERENCES
    Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display.
    • 140
    Generation and isolation of target-specific single-domain antibodies from shark immune repertoires.
    • 25
    Atypical Antigen Recognition Mode of a Shark Immunoglobulin New Antigen Receptor (IgNAR) Variable Domain Characterized by Humanization and Structural Analysis
    • 48
    • PDF
    Engineered protein scaffolds as next-generation antibody therapeutics.
    • 308
    • PDF